Given the ability of the TPTPB to detect prostate cancer at significantly higher rates than TRUS biopsies (8–12), we questioned whether we should move away from TRUS biopsies to TPTPB and whether PSA is actually a more specific biomarker for prostate cancer detection than had been previously thought. This evidence concerns the gene KLK3 and prostate carcinoma.